Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors

NCT07257484 · Not yet recruiting

Last updated 2026-05-28

This clinical trial is testing whether the medication tirzepatide can help postmenopausal women who have survived hormone receptor-positive (HR+) breast cancer and also have obesity.

Status Not yet recruiting Approved but enrollment has not started.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design open-label (no blinding) treatment study

Participants 30 people Planned (estimated).

Who can join Ages 18+ · female only

Timeline Started 2026-04 · est. completion 2027-12

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT07257484 ↗

Description as written by the study sponsor.

This study will explore whether tirzepatide is a practical and acceptable treatment for postmenopausal women with a history of hormone receptor-positive breast cancer and obesity. The investigators aim to understand whether participants are willing and able to take this medication once weekly for 6 months and whether it may help improve weight and overall health. There will be monthly check-ins to monitor progress and safety. At the beginning and end of the study, participants will undergo body composition assessments, blood tests and a stool sample will be collected, and surveys will be completed.

Treatments tested

Tirzepatide Drug

Participants will take tirzepatide weekly for 24 weeks. The dose will be adjusted on a monthly basis as clinically indicated.

Main thing measured	Percentage of participants completing week 24 visit with all required assessments
Sponsor	Weill Medical College of Cornell University
Conditions studied	Obesity (Disorder), Breast Cancer
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07257484 ↗